Skip to main content
Not Found
Digital Seminar

Psychopharmacology: Essential Information for Mental Health Professionals


Speaker:
David Dadiomov, PharmD, BCPP
Duration:
6 Hours 22 Minutes
Language:
Presented in EN, subtitles in EN, handouts in EN
Copyright:
May 02, 2024
Product Code:
POS059667
Media Type:
Digital Seminar - Also available: Live Webinar


Tags: APA


Description

Dr. David Dadiomov, a board certified psychiatric pharmacist with a doctorate in pharmacy and residency training in psychiatric pharmacy, shares his clinical expertise to provide detailed information about the range of common medications prescribed for mental health conditions. You will get the latest information on antidepressants, anxiolytics, and common medications for insomnia and attention deficit/hyperactivity disorder among others. Through lecture, the examination of multi-disciplinary ethics codes and real case examples, you will take a close look at the ethical decisions that accompany medication use and the non-prescribers role and limits with regards to medication discussions with your patients.

Dr. Dadiomov serves as an expert in the field, frequently consulted and educating on best practices relating to psychotropic medications. Real-world clinical cases are used to supplement the material and reinforce complex topics into pertinent components. The most pressing, and frequently requested topics are presented including how to discuss the benefits and risks of medications within the scope of practice with your patients. The goal is for you to leave better prepared to communicate with your clients as well as the prescribers and other interdisciplinary colleagues. Dr. Dadiomov instructs you on how the medications work, their benefits, the side effects, and the most important information to optimize treatment outcomes.

Credit

Program Information

Planning Committee Disclosure - No relevant relationships

All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners.  For speaker disclosures, please see the faculty biography.



Canada Credit - CE Information Coming Soon

Continuing education credit information is coming soon for this non-interactive self-study package.

CEs may be available for select professions, as listed in the target audience. Hours will be dependent on the actual recording time. Please check with your state licensing board or organization for specific requirements. 

There may be an additional fee for CE certificates. Please contact our Customer Service at 1-800-844-8260 for more details. 

**Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of your profession. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.



Handouts

Speaker

David Dadiomov, PharmD, BCPP's Profile

David Dadiomov, PharmD, BCPP Related seminars and products


David Dadiomov, PharmD, BCPP, is an assistant professor of clinical pharmacy in the Titus Family Department of Clinical Pharmacy at the USC Mann School of Pharmacy and Pharmaceutical Sciences.

He holds board certification in psychiatric pharmacy and serves as the director of the PGY2 Psychiatric Pharmacy Residency Program. He has led, co-led and conducted extensive research on opioid use disorders among vulnerable populations, prevalence and distribution of high-risk prescription opioid use, therapeutic drug monitoring, treatment-resistant psychiatric conditions and more. Dr. Dadiomov practices as a clinical pharmacy specialist in addiction and psychiatry at the Complex Care Clinic of the Los Angeles County Department of Health Services, one of the largest of its kind in the United States.

Dr. Dadiomov’s teaching approach is case focused, practical for any clinical setting, interactive and evidence supported. His expertise has been shared with experienced clinicians, graduate students and advanced level students. Dr. Dadiomov is the recipient of multiple awards for clinical excellence, teaching and clinical innovation and has presented, authored and co-authored multiple peer-reviewed journal articles, book chapters, and scientific presentations.

 

Speaker Disclosures:
Financial: Dr. David Dadiomov has employment relationships with the University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, the University of Southern California Psychiatry and Behavioral Sciences Medical Residency, and the Los Angeles County Department of Health Services. He receives a speaking honorarium and recording royalties from Psychotherapy Networker and PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. David Dadiomov is a member of the American Society of Addiction Medicine, the College of Psychiatric and Neurologic Pharmacists, the American College of Clinical Pharmacy, the American Association of Colleges of Pharmacy, and the American Society of Health-System Pharmacists. He is a reviewer for several publications, for a complete list contact PESI.com.


Additional Info

Program Information

Access for Self-Study (Non-Interactive)

Access never expires for this product.

For a more detailed outline that includes times or durations of time, if needed, please contact cepesi@pesi.com.


Questions?

Visit our FAQ page at https://www.pesicanada.ca/faq or contact us at https://www.pesicanada.ca/contact-us.


Objectives

  1. Discuss the proper role of mental health professionals who treat clients receiving both psychotherapeutic medications and psychotherapy.
  2. Describe specific ethical issues and resolutions related to communicating with clients and prescribing professionals about psychotropic medications.
  3. Explain the neurotransmitter systems and neuroanatomy underlying the biological basis for mental disorders and pharmacotherapy.
  4. Identify the major classes of drugs used to treat mental disorders and which mental disorders are appropriately treated with each class of drugs.
  5. Describe adverse effects and drug reactions of the commonly prescribed psychotropic medications and when to alert the prescriber about them.
  6. Analyze the role that half-life plays in the efficacy of insomnia medications prescribed for clients and how it may affect behavioral interventions.

Outline

MEDS 101

  • Case study
  • Reasons to be knowledgeable about psychiatric medications
  • Lessons from other disciplines
  • Pharmacy
  • Nursing
  • Ethics guidelines
  • The common questions clients have about their medications
  • Handling differences of opinion between yourself and a prescribing professional

GENERAL OVERVIEW OF THE NERVOUS SYSTEM

  • Organization of the nervous system
  • Structure of the neuron
  • Communication between neurons
  • How medicines interact with the nervous system

DEPRESSION MEDICATIONS

  • Neurobiology
  • SSRIs and SNRIs
  • Mechanism of action
  • Benefits and adverse reactions
  • Medications in these categories
  • Case study

ANXIETY DISORDER MEDICATIONS

  • DSM-5® anxiety categories
  • Deconstructionist approach taken by prescribers
  • Neurobiology
  • SSRIs and Benzodiazepines
  • Mechanism of action
  • Benefits and adverse reactions
  • Medications in these categories
  • Case study

BIPOLAR MEDICATIONS

  • Monotherapy
  • Lithium, anticonvulsants, and 2nd generation antipsychotics
  • Mechanism of action
  • Benefits and adverse reactions
  • Medications in these categories
  • Case study

ADHD MEDICATIONS

  • Neurobiology
  • Methylphenidate and amphetamine
  • Mechanism of action
  • Delivery systems
  • Benefits and adverse reactions
  • Medications in these categories
  • Case study

ANTIPSYCHOTIC MEDICATIONS

  • Psychosis symptoms
  • Neurobiology
  • 1st and 2nd generation
  • Antipsychotics
  • Mechanism of action
  • Benefits and adverse reactions
  • Medications in these categories
  • Case study

INSOMNIA MEDICATIONS

  • Causes and treatments for insomnia
  • Medications for insomnia
  • Half-life
  • Benefits and adverse reactions
  • Case study

LIMITATIONS OF THE RESEARCH & POTENTIAL RISKS

Target Audience

  • Counselors
  • Social Workers
  • Psychologists
  • Psychotherapists
  • Case Managers
  • Art Therapists
  • Marriage & Family Therapists
  • Nurses
  • Nurse Practitioners
  • Clinical Nurse Specialists
  • Substance Use Disorders Counselors
  • Occupational Therapists
  • Physicians
  • Occupational Therapy Assistants
  • Other Mental Health & Health Care Professionals

Reviews

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesicanada.com.

Please wait ...

Back to Top